Opinion: Topical BRAF Inhibitor Could Reduce Rash in Anti-EGFR Therapy
Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.
The Evolving Role of the Oncology Nurse in Clinical Trials
Oncology nurses are paramount to the success of patients, especially through their work on clinical trials.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.
Case Study: Bridging the Gap for Patients With Metastatic CRC
Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.
FDA Approves Perioperative Pembrolizumab in Head and Neck SCC
The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.
Zanubrutinib Tablets Greenlit by FDA for All Approved Indications
An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.
FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC
UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care
Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.
Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer
The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.
Education Reassures Patients With MM Receiving Subcutaneous Daratumumab
Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse events, according to Stephanie Mompoint, APRN.
AI Tool May Predict Response, Resistance in Advanced RCC
A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.
Creating Safe Spaces for LGBTQIA+ Patients With Cancer
Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ community.
Olanzapine May Reduce Nausea, Vomiting From Radiation
Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.
Pembrolizumab Plus CCRT Could Become SOC in High-Risk Cervical Cancer
Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.
Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL
The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.
May FDA Approvals in Oncology: Firsts in PPGL, Anal Cancer, and More
The FDA approved the first oral treatments for paraganglioma, pheochromocytoma, and anal cancer in May.
Luspatercept Improves Transfusion Independence in Lower-Risk MDS
Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.
Nurses, APPs Can Help Prevent Parkinsonism During Cilta-Cel in Myeloma
By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.
Chemo With Molecular Guidance Improves Survival in Early NSCLC
A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.
Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC
Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.
First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC
The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.
Dermatologic Protocol Preserves QOL in EGFR+ Advanced NSCLC Treatment
COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.
Darolutamide Receives FDA Approval for mCSPC
The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.
Peripheral Neuropathy Treatable With Teliso-V in C–Met-High NSCLC
Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.
PROs Higher For Imlunestrant With/Without Abemaciclib in ER+, HER2– BC
Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.
Niraparib Plus Abiraterone Improves rPFS in HRR-Mutated mCSPC
The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.
T-DXd Rechallenge Tolerable Post Grade 1 ILD in Breast, Solid Tumors
Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.
